Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.
An open-label extension study to evaluate long-term safety of eculizumab in PNH patients who had completed the TRIUMPH (C04-001), SHEPHERD (C04-002), and X03-001 studies.
Inclusion Criteria:
Exclusion Criteria:
Bethesda, Maryland 20892, United States
St Louis, Missouri 63110, United States
Durham, North Carolina 27710, United States
Philadelphia, Pennsylvania 19104, United States
Saint Leonards, New South Wales 2065, Australia
Woolloongabba, Queensland 4102, Australia
Woodville South, South Australia 5011, Australia
Parkville, 3050, Australia
Hanover, D-30625, Germany
Homburg/Saar, D-66421, Germany
Ulm, D-89081, Germany
Florence, 50139, Italy
Naples, 5-80131, Italy